Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Colorcon
Johnson and Johnson
Medtronic
Boehringer Ingelheim

Last Updated: December 3, 2022

CLINICAL TRIALS PROFILE FOR BELINOSTAT


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Belinostat

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00274651 ↗ A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas Terminated Onxeo Phase 2 2006-01-01 Open-label, non-randomized trial to assess the effectiveness of PXD101 in patients with recurrent or refractory cutaneous or peripheral and other types of T-cell lymphomas. PXD101 is a new, potent histone deacetylase (HDAC) inhibitor. Patients are treated with belinostat(PXD101) 1000 mg/m2 on days 1-5 of a 21 day cycle.
NCT00301756 ↗ Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors Completed National Cancer Institute (NCI) Phase 2 2006-09-01 This phase II trial studies how well belinostat works in treating patients with ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer that have spread to other places in the body or ovarian low malignant potential tumors. Belinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT00303953 ↗ PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Completed National Cancer Institute (NCI) Phase 2 2006-01-01 This phase II trial is studying how well PXD101 works in treating patients with relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. PXD101 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
NCT00321594 ↗ Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery Completed National Cancer Institute (NCI) Phase 1/Phase 2 2006-05-01 This phase I/II trial is studying the side effects and best dose of belinostat and to see how well it works in treating patients with liver cancer that cannot be removed by surgery. Belinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
NCT00334789 ↗ Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery Completed National Cancer Institute (NCI) Phase 1 2006-06-12 This phase I trial is studying the side effects and best dose of belinostat when given together with isotretinoin in treating patients with metastatic or unresectable solid tumors. Belinostat may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Isotretinoin may cause solid tumor cells to look more like normal cells, and to grow and spread more slowly. Giving belinostat together with isotretinoin may be an effective treatment for metastatic or unresectable solid tumors.
NCT00348985 ↗ PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas Completed National Cancer Institute (NCI) Phase 1 2006-03-01 This phase I trial is studying the side effects and best dose of PXD101 and bortezomib in treating patients with advanced solid tumors or lymphomas. PXD101 and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PXD101 may also cause cancer cells to look more like normal cells, and to grow and spread more slowly. Giving PXD101 together with bortezomib may kill more cancer cells.
NCT00351975 ↗ Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases Completed National Cancer Institute (NCI) Phase 1 2006-06-01 This phase I trial is studying the side effects and best dose of belinostat when given together with azacitidine in treating patients with advanced hematologic cancers or other diseases. Belinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving belinostat together with azacitidine may kill more cancer cells.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Belinostat

Condition Name

Condition Name for Belinostat
Intervention Trials
Peripheral T-cell Lymphoma 4
Lymphoma 4
Recurrent Adult Diffuse Large Cell Lymphoma 4
Solid Tumor 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Belinostat
Intervention Trials
Lymphoma 18
Lymphoma, T-Cell 12
Carcinoma 8
Leukemia 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Belinostat

Trials by Country

Trials by Country for Belinostat
Location Trials
United States 172
Denmark 6
Canada 5
France 5
United Kingdom 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Belinostat
Location Trials
California 14
Florida 12
Maryland 11
New York 10
Texas 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Belinostat

Clinical Trial Phase

Clinical Trial Phase for Belinostat
Clinical Trial Phase Trials
Phase 3 2
Phase 2 17
Phase 1/Phase 2 8
[disabled in preview] 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Belinostat
Clinical Trial Phase Trials
Completed 27
Recruiting 9
Terminated 8
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Belinostat

Sponsor Name

Sponsor Name for Belinostat
Sponsor Trials
National Cancer Institute (NCI) 23
Onxeo 11
Spectrum Pharmaceuticals, Inc 11
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Belinostat
Sponsor Trials
Industry 41
Other 33
NIH 24
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Express Scripts
McKesson
Medtronic
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.